| Literature DB >> 33218097 |
Badriyah Alhalaili1, Ileana Nicoleta Popescu2, Olfa Kamoun3, Feras Alzubi1, Sami Alawadhia1, Ruxandra Vidu4,5.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is considered a public health emergency of international concern. The 2019 novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused this pandemic has spread rapidly to over 200 countries, and has drastically affected public health and the economies of states at unprecedented levels. In this context, efforts around the world are focusing on solving this problem in several directions of research, by: (i) exploring the origin and evolution of the phylogeny of the SARS-CoV-2 viral genome; (ii) developing nanobiosensors that could be highly effective in detecting the new coronavirus; (iii) finding effective treatments for COVID-19; and (iv) working on vaccine development. In this paper, an overview of the progress made in the development of nanobiosensors for the detection of human coronaviruses (SARS-CoV, SARS-CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV) is presented, along with specific techniques for modifying the surface of nanobiosensors. The newest detection methods of the influenza virus responsible for acute respiratory syndrome were compared with conventional methods, highlighting the newest trends in diagnostics, applications, and challenges of SARS-CoV-2 (COVID-19 causative virus) nanobiosensors.Entities:
Keywords: COVID-19 pandemic; SARS/MERS-CoV; coronavirus 2019-nCoV; influenzas; nanobiosensors; nanomaterials; respiratory virus; virus detection
Mesh:
Year: 2020 PMID: 33218097 PMCID: PMC7698809 DOI: 10.3390/s20226591
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1The animal origins of human coronaviruses (severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV)). Adapted from Rabi et al. [8], licensed CC BY 4.0.
The animal origins of various coronaviruses, the corresponding diseases and some characteristics of them in comparison with influenza viruses a.
| Disease | Flu (swine flu) | SARS 2002 | MERS 2012 | COVID 19 |
|---|---|---|---|---|
| Virus Name | ||||
| Origin of Virus | Bird Influenza A | SARS-like | SARS-like | BaT-CoV RaTG13 |
| Intermediate host | Pig Influenza A | Civet Cat | Camel | Pangolin |
| Incubation period | 1–4 days | 2–7 days | 5 days | 2–14 days |
| Symptoms | Fever, cough, shortness of breath or difficulty breathing, mild respiratory tract infections, sometimes severe and acute diarrhea and acute vomiting | Fever, cough, shortness of breath or difficulty breathing, severe acute respiratory syndrome, 10 % mortality rate | Fever, cough, shortness of breath or difficulty breathing, severe acute respiratory syndrome, 37% mortality rate | Fever, cough, shortness of breath or difficulty breathing, severe acute respiratory syndrome; mortality rate; diarrhea, fatigue, vomiting, muscle or body aches, headache, loss of the sense of smell or taste. |
a Adapted from: [12,63,64,65].
Figure 2Classification of human coronaviruses (HCoVs) from all four gen-groups. HCoVs are marked with red outlines. Adapted from Monajjemi et al. [61], licensed CC BY 4.0.
Figure 3Schematic diagrams of the structural proteins components of SARS-CoV-2 (top), including spike (S) glycoprotein, small envelope (E), matrix (M) protein, and nucleocapsid (N) protein, as well as several accessory proteins [20] (licensed CC BY 4.0), and H1N1 influenza virus structure (bottom), including spikes made up of proteins, such as hemagglutinin (HA) and neuraminidase proteins (NA), matrix protein (M1), and ion channel or M2 protein. Adapted from Besednova et al. [70], licensed CC BY 4.0.
Figure 4Illustration of the mechanism by which coronavirus infection occurs and its mode of replication. Reprinted from Acter et al. [73]. Copyright 2020 with permission from Elsevier.
Figure 5The schematic diagram of different analytes, bioreceptors for biorecognition elements, transducers with integrated nanostructures as parts of a typical nanobiosensor design for respiratory viruses.
Figure 6Schematic representation of different biosensors classifications for the detection of SARS and MERS coronaviruses.
List of laboratory tests recommended with common clinical indicators associated with the COVID-19 tests for adult patients.
| Biomarkers | Normal Patient | Infected Patient | Severe Conditions | Ref. |
|---|---|---|---|---|
| Serum ferritin (ng/mL) | 15.0–150.0 | 800.4 (452.9–1451.6) | Inflammation | [ |
| C-reactive protein (mg/mL) | 0.0–1.0 | 57.9 (20.9–103.2) | Viral infection | [ |
| Interleukin-2R (U/mL) | 223.0–710.0 | 757.0 (528.5–1136.3) | High plasma concertation | [ |
| Cytokines (IL-6) (pg/mL) | 0.0–7.0 | 7.9 | Syndrome related to “cytokine storm” | [ |
| D-Dimer (µg/mL) | 0–0.243 | 0.5 | Abnormal blood coagulation distributed coagulopathy | [ |
| Serum amyloid A (SAA) (mg/L) | 0–10 | 108.4 | Inflammation | [ |
Figure 7Schematic representation of different assay formats in the detection of small molecules. (a) In a direct assay, target analyte attaches to the antibody (recognition element) immobilized on the sensor surface; (b) in a competitive assay, the analyte competes with its conjugate to attach to the antibody; (c) in a binding inhibition assay, the analyte conjugate is the one immobilized on the sensing surface [94]. (Licensed CC BY 4.0).
Electrochemical based nanobiosensors of epidemic/pandemic influenza viruses in comparison with coronaviruses (SARS/MERS-CoV and 2019-nCoV).
| Biological Samples | Nanomaterials | Detection Methods | Target | Limit of Detection (LOD) | Ref. | |
|---|---|---|---|---|---|---|
|
| ||||||
| Biological substances such as DNA and proteins | Graphene | Field-Effect Transistor (FET) | Lectin | LOD: 130 pM | [ | |
| Oligonucleotide sequences derived from an H5N1 avian influenza | rGO reduced graphene oxide | Field-Effect Transistor (FET) | Gene (H5N1) | LOD: 50 pM | [ | |
| Saliva | Nanocrystalline boron-doped diamond | Electrochemical impedance (EIS) | Influenza virus M1 protein | LOD: 5 × 10−14 g/mL | [ | |
| Egg sample | Graphene gold hybrid nanocomposite | Electrochemical impedance EIS) | Influenza A virus | LOD: 10–8 U/mL | [ | |
| Fetal bovine serum, extraneous bovine serum albumin (BSA) | Gold electrode | Electrochemical impedance spectroscopy (EIS) | Human influenza virus type A (H3N2) | LOD: 8 ng/mL | [ | |
| Saliva buffer | Diamond biosensor (nano-scale boron-doped diamond surface sensor) | Electrochemical impedance spectroscopy (EIS) | M1 protein of influenza A virus | LOD: 1 fg/mL | [ | |
| Samples contained bovine serum albumin solution (BSA (0.5%) | Nanostructured hybrid bilayers on gold electrodes | Electrochemical impedance spectroscopy (EIS) | Human influenza A virus (H1N1) | LOD: 0.024 μg/mL | [ | |
| Viral sample of inactivated, but intact influenza viruses H3N2 | Gold electrode | Electrochemical impedance spectroscopy (EIS) | Human influenza A virus (H3N2) | LOD: 1.3 × 104 viruses/mL | [ | |
| Isolated AIV H5N1 sample incubated for 45 min at 37 °C | Magnetic iron oxide (Fe3O4) nanobeads | Electrochemical impedance spectroscopy (EIS) | Avian influenza virus (AIV) (H5N1) | LOD: 0.0128 HA unit/50 μL. | [ | |
| Biological samples with avian influenza virus | Magnetic streptavidin-coated 30 nm nanobeads | Electrochemical impedance spectroscopy (EIS) | Avian influenza virus (AIV) (H5N1) | LOD: 103 EID 50/mL | [ | |
| Inactivated avian influenza virus H5N1 sample | Concanavalin A-glucose oxidase-Au nanoparticles (ConA-GOx-AuNPs) | Electrochemical impedance spectroscopy (EIS) | Avian influenza virus (AIV) (H5N1) | LOD: 0.04 HAU/mL | [ | |
| Commercial sample Spike saliva | Gold paper electrode | Electrochemical Impedance spectroscopy (EIS) | H1N1 antigen | LOD: 4.70 PFU/mL | [ | |
| Influenza viral particles in infected swine nasal samples | Reduced graphene oxide nanosheets (RGO) | Chronoamperometry (CA) | Human influenza A virus (H1N1) | LOD: 0.5 PFU/mL | [ | |
| Virus culture in embryonated chicken egg | Gold nanoparticles (AuNPs) | Chronoamperometry (CA) | Influenza virus (H9N2) | LOD: 16 HAU | [ | |
| Virus samples in chicken embryo cultures | Conducting polymer of PEDOT-poly (3,4-ethylene-dioxythiophene) PSS film | Amperometry | Human influenza A virus (H1N1) | LOD: 0.025 HAU | [ | |
| Commercial ELISA kits Probe sequence (avidin from egg whites) | ZnO-NRs | Amperometry | (H1N1), (H5N1), and (H7N9) influenza | LOD: 1.00 pg/mL | [ | |
| Throat swab samples | Gold electrode | Amperometry | Tetrahedral DNA probe of the H7N9/ssDNA of H7N9 | LOD: 0.750 pM | [ | |
| Analyte samples collected from the throats of live animals, fecal content, and blood | Graphene oxide (GO) nanostructures | Chronoamperometry and | HA proteins of Influenza virus (H5N1)/(H1N1) | LOD: 9.4 pM (Commercial H1N1) | [ | |
| Nasal swab and oropharyngeal samples | Gold screen printed electrode (SPE) | Cyclic voltammetry (CV) | ss-cDNA of the H1N1 | LOD: 0.004 ng in 6 µL | [ | |
| Chicken serum | Gold electrode | Cyclic voltammetry (CV) | HA protein of H5N1 | LOD: 1.00 pM | [ | |
| Negative chicken swab samples | Fe3O4 Magnetic Nanoparticles | Cyclic voltammetry (CV) | Avian influenza virus (AIV) (H5N1) | LOD: 0.367 HAU/mL | [ | |
| Human blood, nasal swab, saliva, and urine | AP-Neu5Ac substrate | Cyclic Voltammetry (CV) | Viral surface of NA-neuraminidase | LOD: 5.6 ng/mL | [ | |
| Cell culture and viral infection cells | Specific anti-PB1-F2 antibody on the surface of the Au micro-electrode modified with polypyrrole bearing ferrocene | Cyclic Voltammetry (CV) | Protein of influenza A virus (PB1-F2) | LOD: 0.42 nM | [ | |
| Human serum | Pt NPs_porous ZnO spheres | Voltammetric (Cyclic Voltammetry) | DNA sequence of influenza virus | LOD: 0.76 pg/mL | [ | |
| Diluted human serum samples spiked | AuNPs | Differential pulse voltammetry (DPV) | H5N1 DNA aptamer/antiH5N1 | LOD: 100 fM | [ | |
| Saliva from a healthy person | Superhydrophobic paper/conductive carbon paste | Differential pulse voltammetry (DPV) | H1N1 antibody/H1N1 antigen | 113 PFU/mL | [ | |
| Antibodies from Hen sera from individuals vaccinated and non-vaccinated | Gold electrode | Osteryoung square wave voltammetry (OSWV) | His6-H5 HA/antiH5N1 | LOD: 2.40 pg/mL | [ | |
| Diluted human and swine serum Vaccinated mice sera | Gold electrode | Osteryoung square wave voltammetry (OSWV). | His6-H1HA/anti-H1N1 | LOD: – | [ | |
| Biological samples | Gold electrode | Osteryoung Square Wave Voltammetry (OSWV) | ssDNA of H5N1/ RNA of the H5N1 | LOD: 3.00 copies/µL | [ | |
| The probe DNA | AuNPs | Voltammetric | Influenza virus type A (H1N1) | LOD: – | [ | |
| Real patient samples | CdS quantum dots (QDs) | Voltammetric | Influenza virus | LOD: 0.06 mM | [ | |
| Infected swine nasal samples | Single walled carbon nanotubes | Conductometry | Swine influenza virus (SIV) (H1N1) | LOD: 180 TCID50/mL | [ | |
| Clinical exhaled breath condensate (EBC) samples | Silicon nanowire (SiNW) | Conductometry | Human influenza A viruses (H1N1) and (H3N2) | LOD: 2.9 viruses/µL | [ | |
| Saliva from a healthy person | Superhydrophobic paper/conductive carbon paste | Differential pulse voltammetry (DPV) | H1N1 antibody/H1N1 antigen | 113 PFU/mL | [ | |
| Antibodies from Hen sera from individuals vaccinated and non-vaccinated | Gold electrode | Osteryoung square wave voltammetry (OSWV) | His6-H5 HA/antiH5N1 | LOD: 2.40 pg/mL | [ | |
|
| ||||||
|
| ||||||
| Streptavidin (S-Av) analyte | Single-walled carbon nanotubes | Field-Effect Transistor (FET) | nucleocapsid (N) protein of the SARS virus | LOD: physiological conditions | [ | |
| Bovine serum albumin | In2O3 nanowire with an AMP (Fibronectin, Fn) | Field-Effect Transistor (FET) | SARS Virus N-Protein | LOD: sub-nanomolar | [ | |
| A 30-mer sequence of SARS Virus | 100 nm sputtered gold film | Cyclic voltammetry | SARS virus sequence | LOD: 7 × 10−6 M | [ | |
| Bovine serum albumin (BSA) and a rabbit immuno- | Au electrodeposition on glassy carbon electrodes (GCEs | Cyclic voltammetry (CV) | 30-mer sequence of the SARS virus | LOD: 15 fmol (30 μL) | [ | |
| DNA sequence of SARS virus | Gold nanoparticles | Cyclic voltammetry | SARS virus sequence | LOD: 2.5 pmol/L | [ | |
| Clinical specimens | Au@Fe3O4 nanocomposite Fe3O4 NPs (for premix A prep | Differential pulse voltammetry (DPV) with a smartphone | RNA of SARS-CoV-2 | LOD: 200 copies/mL | [ | |
| Protein sample of SARS-CoV | - | high electron mobility transistors (HEMTs | SARS-CoV nucleocapsid protein | LOD: 0.003 nM | [ | |
|
| ||||||
| Spiked nasal samples | AuNPs on carbon electrode | Square wave voltammetry (SWV) | Middle East respiratory syndrome coronavirus (MERS-CoV) and human coronavirus (hCoV) | LOD: 0.4 pg/mL | [ | |
|
| ||||||
| Human Nasopharyngeal | Graphene sheet | Field-Effect Transistor (FET) | SARS-CoV-2 spike protein | LOD: 1.6 × 101 pfu/mL in culture medium | [ | |
| Green Monkey Kidney Cell Culture | Membrane-Engineered Vero Cells (Vero/Anti-S1) | Bioelectric Recognition Assay (BERA) | SARS-CoV-2 S1 Spike | LOD: 1 fg/mL | [ | |
| Spiked saliva samples | Fluorine doped tin oxide (FTO) electrode with gold nanoparticle (AuNPs) | Cyclic Voltammetry (CV), | nCovid-19 spike antigen (nCovid-19Ag) | LOD: 90 fM with eCovSens and 120 fM with potentiostat (spiked saliva samples | [ | |
Figure 8(a) Schematic illustration of graphene-based field effect transistor (FET) biosensor mechanism and detection, where SARS-CoV-2 (spheres) binds to antibodies (Y-shapes). (b) Real-time response of COVID-19 FET toward SARS-CoV-2 spike protein. (c) Bionanosensor selectivity response toward two different proteins: SARS-CoV-2 and MERS-CoV. Reprinted from Seo et al. [69]. Copyright 2020 American Chemical Society.
Figure 9Biosensor response given by the variation of voltage in time for different concentrations of biomolecules [4] (licensed CC BY 4.0 from Sensors, 2020).
Optical detection technique, and their properties of human coronaviruses, including recently developed 2019-nCoV nanobiosensors and influenza viruses.
| Biological Samples | Nanomaterials | Detection Methods | Target | Limit of Detection (LOD) | Ref. |
|---|---|---|---|---|---|
|
| |||||
| H5N1 virus in biological samples | Gold nanoparticles (AuNPs) | Localized surface plasmon resonance (LSPR); Colorimetric | H5N1 virus | LOD: 0.086 mU/mL | [ |
| Viral strains, tracheal samples | Optical SPR fiber sensor | Surface plasmon resonance (SPR) | Avian Influenza | LOD: 5.14 × 105 EID50/0.1mL | [ |
| H5N1–infected feces samples | Gold chip | Surface plasmon resonance (SPR) | H5N1 aptamer/H5N1 whole virus | LOD: 200 EID50/mL | [ |
| Infected cells A549 type with wild type virus or with its PB1-F2 knock-out mutant | Immobilization of anti-PB1-F2 anti-body on the surface of Au micro-electrode modified with polypyrrole bearing ferrocene | Surface Plasmon Resonance (SPR) | PB1-F2 protein of influenza A virus | LOD: 0.42 nM | [ |
| Biomolecular samples | Gold sensor | Surface plasmon resonance (SPR) | H5N1 antigen/H5N1 antibody ssDNA of the H1N1 | LOD: 193.3 ng/mL | [ |
| Blood samples | Gold binding polypeptide (GBP)–fusion protein | Localized surface plasmon resonance/SPR imaging (LSPR/SPRi) | Influenza B virus | LOD: 1 pg/mL | [ |
| Chicken serum | Au spike-like nanoparticle (hAuSN) immobilized on the indium-tin-oxide (ITO) substrate | Localized surface plasmon resonance (LSPR) | HA protein from H5N1 | LOD: 1.00 pM | [ |
| Nasal mucosa from flulike syndrome patients | Gold chip | Intensity-modulated surface plasmon resonance (IM-SPR) | Attenuated reassorted H7N9 antigen | 402 copies/mL | [ |
| Clinically isolated virus type H3N2 | Antibody-Gold | Fluorescence localized surface plasmon resonance (FL-LSPR) | H3N2 Virus | LOD: 10 PFU/mL | [ |
| Human serum | DNA triplex with | Fluorescence-fluorescein isothiocyanate assay (FL/FICT) | Gene of H7N9 virus DNA | LOD: 0.14 nM | [ |
| Biological tissue | Quintenary alloyed CdZnSeTeS quantum dots | Near-infrared (NIR) Fluorescence | RNA sequence of influenza virus | LOD: 1 copy/mL | [ |
| Commercial H5N1–Human serum | Ag@SiO2 NPs | Fluorescence | H5N1 aptamer/Recombinant HA protein of H5N1 | LOD: 2.00–3.5 ng/mL | [ |
| Human serum samples | Liposome-based sensor | Spectrophotometry | Influenza virus H5N1 based on enzyme encapsulated liposome | LOD: 0.04 ng/mL | [ |
| Tracheal swabs collected from wild birds | Polydiacetylene (PDA) vesicles | UV-VIS spectrometer | H5N1 antibody/HA of the H5N1 | LOD: 0.530 copies/µL | [ |
| - | Gold nanoparticles (AuNPs) modified with monoclonal anti-hemagglutinin antibody (mAb). | Colorimetric immunosensor | Influenza A virus (IAV) | LOD: 7.8 hemagglutination units (HAU) | [ |
| Viral culture | Gold | Surface enhanced Raman scattering (SERS)-based lateral flow assay (LFA) | Viral particles (VP) | LOD: 1.9 × 104 PFU/mL | [ |
| Viral nucleic acid | BaGdF 5: Yb/Er upconversion nanoparticles (UCNPs) to AuNPs | Luminescence Resonance Energy Transfer (LRET) | H7 hemagglutinin gene sequence | LOD: 7 pM | [ |
|
| |||||
|
| |||||
| Human serum | Gold nanoparticles | Localized surface plasmon coupled fluorescence (LSPCF) | SARS-CoV nucleocapsid protein (N protein) | LOD: 1 pg/mL | [ |
| Rabbit anti-SCVme | Gold micropatterned chip | Surface plasmon resonance (SPR) | GBP-E-SCVme (SARS-CoV) fusion proteins/anti-SCVme | LOD: 0.200 µg/mL | [ |
| Protein sample | – | Surface plasmon resonance (SPR) | SARS-CoV genome sequence (full- length and N-terminal residues 1–7 deleted SARS 3Clpros) | LOD: – | [ |
| Culture sample of SARS protein, enhanced GFP-green fluorescent protein and RFP-red fluorescent protein | poly(hydroxyalkanoate) (PHA) microbead | Fluorescence | SARS-CoV envelope | LOD: – | [ |
| Vero E6 Cells | Green fluorescent protein (GFP) | Fluorescence | The 3a gene encodes a non-structural viral protein of SARS-Coronavirus | LOD. – | [ |
| Protein sample | - | Fluorescence resonance energy transfer (FRET) | SARS coronavirus NTPase/Helicase | LOD: – | [ |
| Upper-strand DNA and fluorescent-dye-conjugated bottom-strand DNA | Graphene oxide (GO) sheet | Fluorescence | SARS-CoV helicase | LOD: – | [ |
| Lung samples cell (A549 human alveolar epithelial cells or inner medullary collecting duct (IMCD) mouse kidney epithelial cells taken after 6 days of infection with SARS-CoV) | - | Flow cytometry | SARS-CoV Spike Fc protein | LOD: – | [ |
| Control samples Unlabeled nucleic acids in solution | - | Flow cytometry based on fluorescence | SARS-hCoV-M | LOD: 26 fmol at an mean fluorescence intensity (MFI) of 5.7 (for SARS-N) | [ |
| Serum samples | Imaging ellipsometry (Real-time spectroscopic ellipsometry detect the protein layer pattern on the microarray surface. | B cells of SARS | LOD: – | [ | |
| Human serum from healthy donor | QDs-conjugated RNA aptamer | optical QDs-based RNA aptamer chip | SARS-CoV N protein | LOD: concentrations as low as 0.1 pg/mL | [ |
| genomic DNA | Functionalized Photonic Nanocrystals | Optical detection | SARS coronavirus antigenic surface protein | [ | |
| Rabbit anti-SARS coronavirus surface antigen (Rabbit anti SCVme) | Gold micropatterned chip | Surface plasmon resonance (SPR) | SARS coronavirus surface antigen (SCVme) | LOD: 0.200 µg/mL | [ |
| Serum samples | Imaging ellipsometry (real-time spectroscopic ellipsometry detects the protein layer pattern on the microarray surface) | B cells of SARS whole inactivated SARS-CoV virions (scFv, b1 and h12 molecule) | LOD:2.2 µg/mL (b1) and 34 µg/mL (h12) | [ | |
| Human serum from healthy donor | QDs-conjugated RNA aptamer | Optical QDs-based | SARS-CoV N protein | LOD: concentrations as low as 0.1 pg ml−1 | [ |
|
| |||||
| Clinical sample | Gold nanoparticles (AuNPs) | Localized surface plasmon resonance (LSPR); Colorimetric assay | MERS-CoV | LOD: 1 pmol/µL | [ |
| Convalescent patient serum | - | Immunofluorescence microscopy | hCoV-EMC/2012 (MERS-CoV) | LOD: 4.1 RNA copies/reaction | [ |
| Synthetic DNA oligonucleotides samples | Silver nanoparticles (AgNPs) | Colorimetric assay | MERS-CoV DNA | LOD: 1.53 nM | [ |
|
| |||||
| Respiratory | Gold nanoislands functionalized (AuNIs) with complementary | Plasmonic photo-thermal (PPT) and localized surface plasmon resonance (LSPR) | SARS-CoV-2 Nucleic acid | LOD: 0.22 pM | [ |
| Clinical samples | - | Fluorescent detection | SARS-CoV-2 RNA | LOD: 2 copies per sample | [ |
| Isolated RNA samples | Gold nanoparticles | Colorimetric assay | RNA sequence of SARS-CoV-2 | LOD: 0.18 ng/µL of RNA | [ |
| Blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients | gold nanoparticle (AuNP) colloids | colorimetric assay | SARS-CoV-2 IgG-IgM combined antibody | LOD: – | [ |
Magneto-optical detection method and their parameters for human coronaviruses including COVID-19 causative virus and influenza viruses.
| Biological Samples | Nano-/Micro Materials | Detection Methods | Target | Limit of Detection (LOD) | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Virus samples in aqueous buffer and human serum | Ag@SiO2 nanoparticles | Metal enhanced fluorescence (MEF) | Influenza H5N1 | LOD: 3.5 ng/mL | [ |
| Clinical virus in complex biological samples | Au/Fe3O4 decorated graphene | Fluorescence | Influenza H1N1 | LOD: 7.27 fg/mL | [ |
| Complex biological samples | Au/iron oxides (Au/IONPs)-decorated graphene | Magnetofluoro immunoassay (Plasmonic-magnetic graphene platform for virus detection) | Influenza H1N1 | LOD: 6.07 pg/mL | [ |
| Clinically isolated human serum samples | Silica-shelled magnetic nanobeads (MagNBs) and gold nanoparticles | Magnetic nano(e)zyme-linked immunosorbent assay (MagLISA) | Influenza virus A | LOD: 5 × 10−12 g/mL (by human eyes) | [ |
|
| |||||
|
| |||||
| Paired human sera and | Multiplexed magnetic microsphere | MMIA- multiplexed magnetic microsphere immunoassay | SARS-CoV and MERS-CoV Immunoglobulin G antibodies specific for recombinant nucleocapsid proteins (from SARS-CoV, and MERS-CoV, hCoVs, 229E, NL63, OC43, HKU1 | LOD: – | [ |
|
| |||||
| SARS-CoV-2 pseudovirus in 200 μL serum samples | Poly (amino ester) with carboxyl groups (PC)-coated magnetic nanoparticle (pcMNPs) | Fluorescence | Viral RNA extraction of SARS-CoV-2 | LOD: 10 copies of pseudovirus | [ |
| Fetal bovine serum (FBS) | Magnetic nanoparticle (MNP) | Optomagnetic sensing | SARS-CoV-2 | LOD: 0.4 fM dynamic Detection range: 3 orders of magnitude and a total assay time of ca. 100 min | [ |
Figure 10(a) Schematic illustration of AuNIs surface functionalization and bioaerosol detection. The surface of the AuINs was functionalized with succinimidyl-ester to detect bioaerosol. (b) In situ phase sensing response of surface functionalization, including the anchor 11-mercaptoundecanoic (11-MUA) and activator EDC/NHS. Reprinted Qiu et al. [219]. Copyright 2020 American Chemical Society.
Figure 11(a) Schematic diagram of a plasmonic biosensor. (b) Schematic illustration of surface modification of Au nanoisland and the thiol-cDNA ligands. (c) Different nucleic acid concentrations measured using the dual-functional LSPR biosensors Reprinted from Qiu et al. [1]. Copyright 2020 American Chemical Society.
Mass sensitive detection method and their parameters for developed SARS-CoV and influenza virus nanobiosensors.
| Biological Samples | Nanomaterials | Detection Methods | Target | Limit of Detection (LOD) | Ref. |
|---|---|---|---|---|---|
|
| |||||
| - | Gold film | Quartz crystal microbalance (QCM) | Hemagglutinin (HA) protein of influenza A virus | LOD: 4.7 × 10−2 µM, (0.26 µg/mL) | [ |
| Sample of human influenza A virus (H1N1) incubated in a chicken egg culture | Poly(EDOT-co- | Quartz crystal microbalance (QCM) | Human influenza A virus H1N1 | LOD: 0.012 HAU | [ |
| Influenza A virus (VR-544, H3N2) samples | QCM | Quartz crystal microbalance (QCM) | Influenza A virions, | LOD: 4 virus particles/mL | [ |
| Commercial H5N3 | Lead zirconate titanate (PZT) piezoelectric disc | Piezoelectric–SPM | H5N3 surface glycoprotein | 105 vp/mL (100 µm thick) | [ |
| Biological sample | – | Surface acoustic wave (SAW) | HA proteins of Influenza A virus sub type H1N1 | LOD: 1 ng /mL | [ |
| commercial H5N3 | Lead zirconate titanate (PZT) piezoelectric disc | Piezoelectric—SPM | 3′SLPAA polymer/H5N3 surface glycoprotein | 105 vp/mL (100 µm thick) | [ |
|
| |||||
|
| |||||
| Sputum | PZ crystal surface | Immunoassay | SARS-CoV | LOD: 0.6 µg/mL | [ |
| Biological sample | Piezoelectric immunosensor | Quartz crystal microbalance (QCM) | SARS-CoV spike protein S1 | – | [ |
| High protein | Aptamer coated paramagnetic | Piezoelectric | SARS-CoV helicase protein | LOD: 3.5 ng/mL | [ |
|
| |||||
| Oral swab samples | Nanoparticles | Quartz crystal microbalance (QCM) | SARS-CoV-2 | – | [ |